HALO Halozyme Therapeutics Inc

Price (delayed)

$42.04

Market cap

$5.98B

P/E Ratio

25.48

Dividend/share

N/A

EPS

$1.65

Enterprise value

$6.41B

Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in ...

Highlights
HALO's gross profit has soared by 161% YoY and by 23% QoQ
The company's revenue has surged by 129% YoY and by 25% QoQ
The debt has soared by 124% YoY
Halozyme Therapeutics's quick ratio has plunged by 51% YoY

Key stats

What are the main financial stats of HALO
Market
Shares outstanding
142.33M
Market cap
$5.98B
Enterprise value
$6.41B
Valuations
Price to earnings (P/E)
25.48
Price to book (P/B)
49.99
Price to sales (P/S)
14.52
EV/EBIT
26.4
EV/EBITDA
26.07
EV/Sales
15.54
Earnings
Revenue
$412.5M
EBIT
$242.86M
EBITDA
$245.94M
Free cash flow
$149.85M
Per share
EPS
$1.65
Free cash flow per share
$1.05
Book value per share
$0.84
Revenue per share
$2.89
TBVPS
$7.2
Balance sheet
Total assets
$1.03B
Total liabilities
$906.12M
Debt
$874.74M
Equity
$119.75M
Working capital
$885.5M
Liquidity
Debt to equity
7.3
Current ratio
8.75
Quick ratio
7.96
Net debt/EBITDA
1.74
Margins
EBITDA margin
59.6%
Gross margin
82.3%
Net margin
55.4%
Operating margin
63.4%
Efficiency
Return on assets
29.5%
Return on equity
209.2%
Return on invested capital
25.5%
Return on capital employed
26.6%
Return on sales
58.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HALO stock price

How has the Halozyme Therapeutics stock price performed over time
Intraday
-0.02%
1 week
1.94%
1 month
3.24%
1 year
49.98%
YTD
-1.57%
QTD
-7.42%

Financial performance

How have Halozyme Therapeutics's revenue and profit performed over time
Revenue
$412.5M
Gross profit
$339.42M
Operating income
$261.71M
Net income
$228.72M
Gross margin
82.3%
Net margin
55.4%
HALO's gross profit has soared by 161% YoY and by 23% QoQ
The company's revenue has surged by 129% YoY and by 25% QoQ
HALO's net income is up by 40% since the previous quarter
The company's operating income rose by 32% QoQ

Growth

What is Halozyme Therapeutics's growth rate over time

Valuation

What is Halozyme Therapeutics stock price valuation
P/E
25.48
P/B
49.99
P/S
14.52
EV/EBIT
26.4
EV/EBITDA
26.07
EV/Sales
15.54
The stock's price to earnings (P/E) is 60% less than its last 4 quarters average of 63.3
HALO's EPS is up by 38% since the previous quarter
HALO's price to book (P/B) is 84% higher than its 5-year quarterly average of 27.2 but 6% lower than its last 4 quarters average of 53.0
The company's equity has surged by 77% QoQ and by 13% YoY
The company's revenue has surged by 129% YoY and by 25% QoQ
The price to sales (P/S) is 20% lower than the last 4 quarters average of 18.2 but 9% higher than the 5-year quarterly average of 13.3

Efficiency

How efficient is Halozyme Therapeutics business performance
The ROE has grown by 36% from the previous quarter
Halozyme Therapeutics's return on assets has increased by 18% QoQ
HALO's return on invested capital is up by 14% since the previous quarter
HALO's return on sales is up by 8% since the previous quarter

Dividends

What is HALO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HALO.

Financial health

How did Halozyme Therapeutics financials performed over time
The company's total assets is 13% higher than its total liabilities
The total liabilities has surged by 115% year-on-year
The company's total assets has surged by 95% YoY and by 6% QoQ
The debt has soared by 124% YoY
Halozyme Therapeutics's debt to equity has soared by 98% YoY but it has decreased by 44% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.